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Abstract
Background: Fluralaner is a novel systemic ectoparasiticide for cats providing immediate and persistent flea- and
tick-control after a single topical dose. Emodepsid and praziquantel are routinely used to control intestinal worm
infections in cats. The safety of concurrent use of fluralaner and a commercially available emodepsid-praziquantel
combination topical solution was investigated using topical administrations at the maximum recommended dose
rates.
Findings: Few mild and transient clinical findings like erythema at the administration site and single incidences of
salivation or vomiting were observed. All of which were consistent with the individual product leaflets. There were
no findings suggesting an increased safety risk associated with the concurrent treatment of cats with fluralaner and
emodepsid-praziquantel.
Conclusions: Concurrent treatment with fluralaner, emodepsid and praziquantel is well tolerated in cats.
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Findings
Fluralaner is a novel isoxazoline class compound that
provides fast and persistent insecticidal and acaricidal ef-
ficacy in cats [1]. Following topical administration flura-
laner is absorbed transdermally [2] providing at least
12 weeks of flea- and tick-control (Ctenocephalides felis,
Ixodes ricinus) after a single dose [1]. Fluralaner was
shown to be safe when administered topically at over-
doses of up to 5 times the maximum clinical dose, i.e.
up to 465 mg fluralaner/kg body weight, at 8-week inter-
vals in healthy cats [1] and when administered off label
orally, to mimic accidental lick-off following topical ad-
ministration, at the maximum clinical dose of 93 mg
fluralaner/kg body weight [1]. Emodepsid is active
against larval and adult stages of intestinal nematodes,
and praziquantel is active against cestodes in cats [3].
Cats may concurrently be infested with ticks, fleas and
intestinal helminths, e.g. with Dipylidium caninum (flea
tapeworm) transmitted during flea infestation. Therefore,
veterinarians may choose to administer an ectoparasiticide
like fluralaner concurrently with endoparasiticides such as
emodepsid and praziquantel. Fluralaner (Bravecto Spot-on
solution™; MSD Animal Health) and emodepsid/prazi-
quantel (Profender™; Bayer Animal Health GmbH) are
topical formulations with transdermal absorption follow-
ing administration. Both products may potentially be asso-
ciated with mild and transient adverse events following
treatment, as specified on the products’ labels. These
include salivation and vomiting, potentially a result of the
cat licking the application site immediately after treat-
ment, or erythema, alopecia and pruritus at the topical
administration site [1, 3].
This study evaluated the safety of concurrent use of
fluralaner and an emodepsid-praziquantel combination
in healthy cats at the recommended treatment doses.
Twenty healthy European mixed breed cats (ten males
and ten females) were included in the study.
Twenty cats 1.3–6.6 (mean 2.5) years of age and
weighing 2.1–6.4 (mean 3.9) kg were allocated to two
study groups by sorting within gender according to
descending body weight and then random allocation to a
group. Cats of the control group were topically adminis-
tered emodepsid-praziquantel at a dose of 6.25 mg/
25 mg/kg body weight on six occasions at 4-week inter-
vals. Cats of the treatment group also received
emodepsid-praziquantel at the same dose and schedule,
together with fluralaner at 93 mg/kg body weight on
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three occasions at 8-week intervals, i.e. immediately
after the first, third and fifth emodepsid-praziquantel
administration (Table 1). The emodepsid-praziquantel
solution was administered at the base of the skull,
and fluralaner was administered caudal thereof on the
three days when both products were administered
concurrently (days 0, 56, 112).
Cats of both groups were observed for general health
twice daily throughout the study and body weights were
recorded weekly. All cats were examined by a veterinar-
ian on the day prior to each topical treatment, 16 days
following each topical treatment and at the end of the
study (day 167). Examinations included assessments for
abnormalities in behavior, locomotion, musculoskeletal
system, coat, skin, superficial lymph nodes, eyes, pupils,
ears, oral cavity, mucous membranes, capillary refill
time, respiration, auscultation of heart and respiratory
tract, heart rate, respiratory rate, pulse, abdominal palpa-
tion, rectal temperature, any other visible abnormalities
and body condition. In addition, all cats were observed
for general health during the first hour following each
treatment, and were assessed by a veterinarian prior to
each treatment and 1, 2, 4, 6, 12, 24, 36, 48, 60, 72, 96,
120, 144 and 168 h following each treatment for abnor-
malities in behavior, locomotion, respiration, cardiovas-
cular system, eyes/pupils, coat and site of application,
pruritus, salivation and cage side findings.
Throughout the 24-week study period, there were no
findings that were considered to be related to the
concurrent treatment with fluralaner and emodepsid-
praziquantel (treatment group). In the treatment group
transient erythema was observed in two cats at the
emodepsid-praziquantel administration site (two days
after the 3rd treatment occasion; and one day after the
5th treatment occasion), one cat had a small amount of
saliva in the cage four hours after the 1st treatment occa-
sion and one cat had vomited two days after the 5th
treatment occasion. In the control group one cat had
vomited two days after the 3rd treatment occasion and
another cat one day after the 4th treatment occasion. All
of these observations were mild and transient and none
required treatment or affected the general health condi-
tion of the cats. These observations are consistent with
the potential adverse events specified on the individual
product leaflets. There were no findings suggesting an
increased safety risk associated with the concurrent
treatment of cats with fluralaner and emodepsid-
praziquantel.
Other clinical observations, which included one case
of sporadic coughing, one case of sporadic sneezing and
one case of mild skin irritation on the chin in the treat-
ment group, are considered to be findings commonly
observed in a cat colony. These findings were also
minor, transient and none required treatment or affected
the general health condition of the cats.
There were no obvious changes in bodyweights during
the study (Table 1), and the statistical analysis using
mixed models analysis of variance for a repeated mea-
sures design did not reveal any statistically significant
differences between groups (P = 0.7070).
No unexpected clinical observations were observed
over this extended study period, with multiple consecu-
tive treatments with fluralaner and an emodepsid-
praziquantel combination. The study results support the
safe concurrent use of these products and are consistent
with previous data showing no interactions between
fluralaner and other routinely used veterinary medicinal
products in cats [1] or dogs [4–8].
Conclusion
Concurrent treatment with fluralaner, emodepsid and
praziquantel is well tolerated in cats.
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Table 1 Study group details for evaluation of the safety of
fluralaner and emodepsid-praziquantel when administered
concurrently to cats
Control group Treatment group
Emodepsid-praziquantel
treatment days
0, 28, 56, 84,
112, 140
0, 28, 56, 84,
112, 140










Gender Male 5 5
Female 5 5
Body weight (kg)
on study day -1
Mean ± SD 4.0 ± 1.4 3.8 ± 1.3
Body weight (kg)
on study day 168
Mean ± SD 4.1 ± 1.4 4.0 ± 1.5
SD standard deviation
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